Skip to content

A Single-Arm, Virtual Clinical Trial to Evaluate the Effects of a Sleep Supporting Beverage and Two Coffee Substitute Products

A Single-Arm, Virtual Clinical Trial to Evaluate the Effects of a Sleep Supporting Beverage and Two Coffee Substitute Products

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06146517
Enrollment
32
Registered
2023-11-24
Start date
2023-08-31
Completion date
2024-01-22
Last updated
2024-08-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety, Caffeine Withdrawal, Mood, Productivity, Sleep

Brief summary

This is a virtual, single-arm clinical trial that will last 12 weeks. Participants will trial three different products, each for 4 weeks. Participants will trial Clevr Blends Sleeptime during weeks 1-4, Clevr Matcha for weeks 5-8, and Clevr Blends Chai for weeks 9-12. Participants will complete questionnaires at Baseline and Week 2, 4, 6, 8, 10, and 12. In addition to data will be collected from participants' sleep tracking devices at Baseline, Week 2, and Week 4.

Interventions

OTHERClevr Sleeptime

Participants will trial Clevr Blends Sleeptime during weeks 1-4.

OTHERClevr Matcha

Participants will trial Clevr Matcha during weeks 5-8.

OTHERClevr Chai

Participants will trial Clevr Chai during weeks 9-12.

Sponsors

Citruslabs
CollaboratorINDUSTRY
Clevr Blends
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
28 Years to 42 Years
Healthy volunteers
Yes

Inclusion criteria

* Female. * Age 28-42. * Generally healthy without any uncontrolled or chronic disease. * Must consume a beverage containing low to moderate amount of caffeine once daily, defined as consuming the caffeine equivalent of less than or equal to one cup of coffee daily. * Looking for healthier alternatives to caffeine. * Currently owns a wearable sleep tracking device (e.g. Fitbit, Whoop, Oura etc) and has been wearing consistently for 4 weeks. * Resident of the USA.

Exclusion criteria

* Allergies to any of the ingredients in the three products. * Anyone with a formal diagnosis of insomnia. * Any pre-existing or chronic conditions that would prevent participants from adhering to the protocol. * Women that are pregnant, breastfeeding or attempting to conceive during the duration of the trial. * Unwilling to follow the protocol. * Participants that consume more than two caffeinated drinks daily. * Participants that have little to no caffeine daily, equivalent to less than 1 cup of coffee daily. * Is not a resident of the USA.

Design outcomes

Primary

MeasureTime frameDescription
Change in sleep quantity as recorded by wearable sleep tracking device. [Timeframe Baseline to Week 4]4 weeksAll participants will wear a sleep tracking device (e.g. Fitbit, Whoop, Oura etc) to record their total time asleep each night.
Changes in scores on the Sleep Quality Scale (SQS). [Timeframe Baseline to Week 4]4 weeksConsisting of 28 items, the SQS evaluates six domains of sleep quality: daytime symptoms, restoration after sleep, problems initiating and maintaining sleep, difficulty waking, and sleep satisfaction. Using a four-point, Likert-type scale, respondents indicate how frequently they exhibit certain sleep behaviors (0 = few, 1 = sometimes, 2 = often, and 3 = almost always).
Changes in self-reported energy levels. [Timeframe: Baseline to Week 12]12 weeksMeasured via study-specific questionnaires. Participants will answer on a Likert scale (0-5) with 0 indicating the best score and 5 indicating the worse score.
Changes in self-reported cognitive function. [Timeframe: Baseline to Week 12]12 weeksMeasured via study-specific questionnaires. Participants will answer on a Likert scale (0-5) with 0 indicating the best score and 5 indicating the worse score.

Secondary

MeasureTime frameDescription
Changes in self-reported caffeine side effects,12 weeksMeasured via study-specific questionnaires reviewing jitters, caffeine crashes, anxiety, negative moods and dependency. Participants will answer on a Likert scale (0-5) with 0 indicating the best score and 5 indicating the worse score.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026